Background The aim of the study was to compare the efficacy and safety of bivalirudin
versus unfractionated heparin (UFH) in patients with acute myocardial infarction who …

Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients
undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would …

Aims The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary
intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial …

Importance The safety and efficacy of bivalirudin compared with heparin with or without
glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing …

BACKGROUND: Bivalirudin is replacing heparin as the anticoagulant agent of choice for
elective percutaneous coronary intervention (PCI). This study aimed to assess the safety and …

Introduction: Anticoagulant therapy is critical to prevent ischemic recurrences and
complications in acute coronary syndrome (ACS) patients undergoing percutaneous …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …

Background The aim of this study was to assess the impact of bivalirudin, as compared to
unfractionated heparin, on clinical outcomes in patients with ST‐segment elevation …

Methods: We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane
Database of Systematic Reviews, Scopus, and Web of Science from database inception in …